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Poster Session-II 1550.8 mg/kg often failed to achieve our target AUC of 1150–1350. Fif-
teen AML/MDS patients receiving 0.8 mg/kg had a mean AUC of
1059 (822–1653), with 12 AUCs\1150. Subsequently, our routine
starting dose of IV Bu was changed to 0.9 mg/kg.
Methods: We performed a retrospective review of AML and
MDS patients from an IRB approved HIPAA compliant database es-
tablished for the collection and analysis of Bu PK. Data from two
groups of Bu patients treated between 1998 and 2008 were analyzed.
Fifty-eight patients were treated with oral Bu (1 mg/kg) and fifty-
eight patients were treated with IV Bu (0.9 mg/kg). Bu AUC was de-
termined for the first dose and adjustments were made on subsequent
doses to target an AUC of 1150–1350.
Results: Median age for IV and oral Bu patients was 42 (18–68)
and 47 (23–67), respectively (p 5 0.0049). The mean terminal half-
life (T1⁄2 ) was 186 minutes (131–253) for IV Bu and 181 minutes
(110–305) for oral Bu (p 5 NS). Mean AUCs were 1115 (777–
1569) for IV Bu patients and 1260 (654–2019) for oral Bu (p 5
0.0094). Seventeen (29.3%) patients in each group achieved AUCs
within our target of 1150–1350. Thirty-four (58.6%) IV Bu patients
had AUCs\1150 compared to twenty (34.5%) oral Bu patients (p5
0.0092). Eight (13.8%) IV Bu patients had AUCs .1350 compared
to twenty-one (36.2%) oral Bu patients (p 5 0.0053).
Conclusions: While first dose PK analysis showed similar T1⁄2 for
IV and oral Bu, the AUCs achieved with 0.9 mg/kg IV Bu are lower
than with 1mg/kg oral Bu dosing. First-dose AUC from recipients of
IV Bu had a lower variance than AUC from recipients of oral Bu.
Despite changing our starting IV Bu dosing from 0.8 mg/kg to
0.9 mg/kg, the majority of patients still require therapeutic drug
monitoring with dose adjustments to obtain our desired target
AUC of 1150–1350.442
ARETROSPECTIVE ANALYSIS OF RISK FACTORS THAT INFLUENCE INTRA-
VENOUS BUSULFAN KINETICS IN ADULT PATIENTS
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Busulfan (Bu) is a bifunctional alkylating agent that is a common
component of conditioning regimens prior to hematopoetic stem
cell transplantation (HSCT). Bu pharmacokinetics, either with area
under the curve (AUC) or average concentration at steady state
(Css), can be utilized to evaluate efficacy and prevent adverse effects
such as hepatic veno-occlusive disease (VOD). Pharmacokinetic
models that predict Bu levels were historically performed with q 6
hour oral dosing in the pediatric population and used a limited linear
regression model. Since the advent of intravenous (IV) Bu, a consistent
pharmacokinetic modeling system based on specific patient parame-
ters has not emerged. Likewise, current Bu pharmacokinetics models
may not be accurate in adult patients or with once-daily dosing sch-
edules. We will report a retrospective study of approximately 300
patients and present a predictive pharmacokinetic model for appropri-
ate AUC with once-daily IV Bu in adult patients. Our model will be
based on first dose kinetic analyses. We will also evaluate currently
published risk factors that may influence IV Bu kinetic parameters us-
ing univariate, multivariate and stepwise Cox regression analyses. Age,
race, gender, disease state, disease status at time of transplantation,
number of previous chemotherapy regimens, renal and hepatic func-
tion at time of transplant and graft source will be evaluated. Long-
term outcomes to be examined include overall mortality, probability
of survival, development of acute and chronic graft versus host disease
(GVHD), development of VOD and days until neutrophil and platelet
engraftment. Statistical model design and specific data results will be
presented at the 2009 ASBMT Annual Conference.443
AN ANALYSIS OF TOXICITIES AND TIME TO ENGRAFTMENT ASSOCIATED
WITH THREE DISTINCT MELPHALAN TREATMENT SCHEMAS IN PA-
TIENTS WITH MULTIPLE MYELOMA RECEIVING AUTOLOGOUS HEMATO-
POETIC STEM CELL TRANSPLANTATION
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At MD Anderson Cancer Center, the standard-of-care prepara-
tory regimen in patients with multiple myeloma receiving an autol-
ogous stem cell transplant is melphalan 200 mg/m2 given over two
days with one day of rest prior to transplant. The primary objective
of this study is to determine if differences exist in the severity of tox-
icities in patients with multiple myeloma who receive melphalan as
a preparatory regimen in three distinct treatment schema. The sec-
ondary objective of this study is to ascertain the differences in time
to engraftment in this population. Toxicities, defined as nausea,
vomiting, diarrhea, renal and hepatic dysfunction, were graded using
the NCI-CTCAE. Pain secondary to mucositis was recorded based
on the use of patient-controlled analgesia. We performed a retro-
spective review in patients who received one of the following prepa-
ratory regimens: arm 1) melphalan 200 mg/m2 over days -3 and -2,
arm 2) melphalan 200 mg/m2 over day -2, or arm 3) melphalan
200 mg/m2 over days -2 and -1. This review included patients over
the age of 18 in first remission or with primary refractory disease
who received autologous transplantation within 12 months of diag-
nosis. Patients who received prior transplantation were excluded
from this review. 164 patients were identified from the institutional
database for data collection and 100 patients were selected at random
for this interim analysis. The majority of patients identified were
male,\65, ISS stage of I-II, and had an ECOG performance status
of 0–1. With respect to the primary endpoint, no statistically signif-
icant differences were observed in the severity of toxicity when com-
paring the treatment schemas (nausea: p5 0.55; vomiting: p5 0.46;
diarrhea: 0.52, Kruskal-Wallis test and PCA use secondary to mu-
cositis: p 5 0.82, Fisher’s exact test). With regard to time to en-
graftment, the actual difference between the arms was
approximately 1 day, yet the comparison between the three groups
was statistically significant (p\0.001, log-rank test). We concluded
that differences between the three treatment schemas in the severity
of toxicities were neither statistically nor clinically significant; the
differences in time to engraftment were not clinically significant.
Based on the interim analysis, this review demonstrates the poten-
tial for melphalan to be administered in any one of three distinct
treatment schemas without resulting in adverse effects on toxicity
and time to engraftment.
Results
Arm 1 Arm 2 Arm 3Grade 3-4 Toxicity(N544) (N537) (N519)n (%) n (%) n (%)Nausea 2 (4.5%) 1 (2.7%) 0
Vomiting 2 (4.5%) 0 0
Diarrhea 0 2 (5.4%) 0
Serum creatinine 0 0 0
Total bilirubin 0 1 (2.7%) 0
Pain 5 (11.4%) 4 (10.8%) 1 (5.3%)
Time to engraftment (median) 10 days 11 days 10 days444
SUCESSFUL OUTCOME AFTER ACCIDENTAL HIGH DOSE CYTARABINE (HI-
DAC) INFUSION SEVEN DAYS POST UNRELATED DONOR (UD) CORD
BLOOD (CB) STEM CELL TRANSPLATION (SCT)
Stelts, S., Nath, R. Methodist University Hospital/University of Tennessee
Cancer Institute, Memphis, TN
Introduction:The complex regimens of allogenic SCT increase
the risk of medication errors. We report an accidental HIDAC infu-
sion post UD-CBSCT and the patient outcome.
Case Report: A 24 year old heavily pretreated female with history
of relapsed philadelphia (Ph) positive acute lymphoblastic leukemia
received a 4/6 matched UD-CBST. The patient received a prepara-
tory regimen of fludarabine 30 mg/m2 on days -7 to -3, melphalan
70 mg/m2 on day -3 and -2, and antithymocyte immunoglobulin
10mg/kg on days -4 and -2. Graft versus host disease (gvhd) prophy-
laxis consisted of tacrolimus (level 5 -15 ng/ml) and mycophenolate
